Hamlin Capital Management LLC Sells 21,671 Shares of Johnson & Johnson $JNJ

Hamlin Capital Management LLC lowered its position in shares of Johnson & Johnson (NYSE:JNJ) by 2.9% in the second quarter, according to the company in its most recent filing with the SEC. The firm owned 714,820 shares of the company’s stock after selling 21,671 shares during the quarter. Johnson & Johnson comprises about 4.1% of Hamlin Capital Management LLC’s portfolio, making the stock its 10th largest position. Hamlin Capital Management LLC’s holdings in Johnson & Johnson were worth $181,543,000 at the end of the most recent reporting period.

Several other large investors have also added to or reduced their stakes in the company. Blueline Advisors LLC acquired a new stake in shares of Johnson & Johnson during the fourth quarter worth about $25,000. Cresta Advisors Ltd. acquired a new position in Johnson & Johnson in the 4th quarter worth approximately $26,000. DecisionPoint Financial LLC raised its position in Johnson & Johnson by 104.2% during the 4th quarter. DecisionPoint Financial LLC now owns 147 shares of the company’s stock worth $30,000 after buying an additional 75 shares during the last quarter. Family CFO Inc acquired a new stake in Johnson & Johnson during the 4th quarter valued at approximately $31,000. Finally, Bay Harbor Wealth Management LLC lifted its stake in Johnson & Johnson by 49.0% during the 4th quarter. Bay Harbor Wealth Management LLC now owns 149 shares of the company’s stock valued at $31,000 after acquiring an additional 49 shares during the period. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Insider Activity

In related news, EVP Vanessa Broadhurst sold 23,054 shares of the company’s stock in a transaction dated Monday, July 20th. The stock was sold at an average price of $251.27, for a total value of $5,792,778.58. Following the completion of the transaction, the executive vice president owned 23,003 shares of the company’s stock, valued at approximately $5,779,963.81. This represents a 50.06% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Kathryn E. Wengel sold 10,000 shares of the stock in a transaction that occurred on Thursday, June 11th. The stock was sold at an average price of $241.15, for a total value of $2,411,500.00. Following the transaction, the executive vice president owned 114,288 shares in the company, valued at $27,560,551.20. This represents a 8.05% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Corporate insiders own 0.16% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have recently weighed in on JNJ. Daiwa Securities Group increased their price objective on shares of Johnson & Johnson from $237.00 to $246.00 and gave the stock an “outperform” rating in a research note on Thursday, April 16th. The Goldman Sachs Group restated a “buy” rating and set a $282.00 target price on shares of Johnson & Johnson in a research report on Thursday, July 16th. Barclays upped their price target on shares of Johnson & Johnson from $234.00 to $255.00 and gave the company an “equal weight” rating in a report on Wednesday, April 15th. Raymond James Financial set a $280.00 price target on Johnson & Johnson in a research report on Monday. Finally, Johnson Rice reissued a “buy” rating on shares of Johnson & Johnson in a report on Monday. One research analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and six have given a Hold rating to the company. Based on data from MarketBeat, Johnson & Johnson presently has a consensus rating of “Moderate Buy” and a consensus price target of $267.48.

Johnson & Johnson Price Performance

NYSE:JNJ opened at $257.77 on Thursday. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.09 and a quick ratio of 0.81. The firm has a market cap of $621.21 billion, a price-to-earnings ratio of 29.87, a price-to-earnings-growth ratio of 2.42 and a beta of 0.24. The company has a 50 day moving average price of $247.27 and a 200-day moving average price of $239.32. Johnson & Johnson has a 1-year low of $169.68 and a 1-year high of $274.90.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Wednesday, July 15th. The company reported $2.90 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.84 by $0.06. The firm had revenue of $25.31 billion for the quarter, compared to the consensus estimate of $25.06 billion. Johnson & Johnson had a net margin of 21.48% and a return on equity of 32.42%. The firm’s quarterly revenue was up 6.6% compared to the same quarter last year. During the same period in the prior year, the firm posted $2.77 earnings per share. Johnson & Johnson has set its FY 2026 guidance at 11.600-11.750 EPS. Equities research analysts forecast that Johnson & Johnson will post 11.69 EPS for the current year.

Johnson & Johnson Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 8th. Shareholders of record on Tuesday, August 25th will be given a $1.34 dividend. The ex-dividend date is Tuesday, August 25th. This represents a $5.36 dividend on an annualized basis and a dividend yield of 2.1%. Johnson & Johnson’s dividend payout ratio is 62.11%.

Key Headlines Impacting Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: FDA clearance expands J&J’s growth opportunities. The FDA authorized Johnson & Johnson’s OTTAVA robotic surgery system, marking the company’s entry into surgical robotics. Investors may view the platform as a long-term medical-device growth driver and a way to diversify beyond pharmaceuticals. Johnson & Johnson Gets FDA Nod for OTTAVA
• Positive Sentiment: Analysts continue to support JNJ’s outlook. Wells Fargo reportedly expects the stock to rise, while other market commentary identifies Johnson & Johnson as an attractive blue-chip and dependable dividend stock. The company’s latest quarter also showed earnings and revenue exceeding estimates, with full-year 2026 earnings guidance maintained at $11.60-$11.75 per share. Wells Fargo Analyst Expects Johnson & Johnson Stock to Rise
• Positive Sentiment: Dividend appeal is supporting defensive demand. JNJ is being highlighted alongside other Dividend Aristocrats for dependable income. Its large scale, 21.48% net margin, 32.42% return on equity and low-beta profile may appeal to investors seeking stability while broader equity valuations remain elevated. Strong Buy Dividend Aristocrat Stocks
• Neutral Sentiment: Leadership transition adds a near-term watchpoint. Innovative Medicine chairman Jennifer Taubert will retire after more than two decades at J&J, with Tom Cavanaugh set to succeed her in September. Taubert helped build the segment into a business generating more than $60 billion in annual revenue, making execution under the new leader important for investors. Johnson & Johnson Leadership Change

About Johnson & Johnson

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.